Toni Trate, DO
General Practice · Farmington Hills, MINPI 1164468690
Payments from drug & device makers
Across 240 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$584
- Pfizer$571
- AbbVie$405
- Novo Nordisk$335
- Amgen$285
- Lundbeck LLC$275
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,025100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 36 | $584 |
| Pfizer | 47 | $571 |
| AbbVie(2 entities) | 24 | $405 |
| Novo Nordisk | 22 | $335 |
| Amgen(2 entities) | 15 | $285 |
| Lundbeck LLC | 14 | $275 |
| Teva Pharmaceuticals USA, Inc. | 14 | $264 |
| Boehringer Ingelheim | 13 | $251 |
| Supernus Pharmaceuticals, Inc. | 9 | $218 |
| GSK | 10 | $169 |
| AstraZeneca | 6 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $99 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Novartis | 2 | $41 |
| Harmony Biosciences LLC | 2 | $40 |
| Verona Pharma, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Circassia Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $13 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$110
How this compares
$4,025 in reported general payments places this provider in the 95th percentile of 3,051 general practice providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 49 | $50,891 |
| FarxigaDapagliflozin Propanediol | 76 | $44,235 |
| OzempicSemaglutide | 35 | $42,020 |
| EliquisApixaban | 37 | $35,854 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $29,149 |
| TrulicityDulaglutide | 24 | $26,134 |
| MounjaroTirzepatide | 25 | $25,776 |
| Repatha SureclickEvolocumab | 40 | $24,830 |
| RexultiBrexpiprazole | 13 | $20,847 |
| ZenpepLipase/Protease/Amylase | 11 | $17,439 |
| XareltoRivaroxaban | 23 | $17,429 |
| EntrestoSacubitril/Valsartan | 13 | $15,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,861 |
| Bydureon BciseExenatide Microspheres | 16 | $13,263 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $104 | $62,071115 claims |
| Boehringer IngelheimJardiance, Tradjenta | $251 | $56,50860 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $584 | $51,91049 claims |
| Novo NordiskOzempic | $335 | $42,02035 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $169 | $38,63470 claims |
| PfizerEliquis | $571 | $35,85437 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $65 | $20,84713 claims |
| NovartisEntresto | $41 | $15,68613 claims |
| Indivior Inc.Suboxone | $12 | $5,52315 claims |
| AbbVieCreon | $405 | $4,23812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,051 general practice providers in Michigan.
Other general practice in Farmington Hills
- Amanda NahhasFarmington Hills$9K
- Anil PrasadTaylor$1.7M
- Sadeer DaoodDearborn$1.1M
- Shakib HalabuWest Bloomfield$1.1M
- Dennis FasbinderAnn Arbor$758K
- Christian GrothAnn Arbor$283K
- Kevin BoneSaginaw$125K
- David JulianiRochester Hills$106K
- Marie FluentAnn Arbor$106K
- Howard KormanRoyal Oak$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.